178 related articles for article (PubMed ID: 33303645)
1. Targeting PIM Kinases to Overcome Therapeutic Resistance in Cancer.
Toth RK; Warfel NA
Mol Cancer Ther; 2021 Jan; 20(1):3-10. PubMed ID: 33303645
[TBL] [Abstract][Full Text] [Related]
2. PIM kinase (and Akt) biology and signaling in tumors.
Warfel NA; Kraft AS
Pharmacol Ther; 2015 Jul; 151():41-9. PubMed ID: 25749412
[TBL] [Abstract][Full Text] [Related]
3. Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer.
Malone T; Schäfer L; Simon N; Heavey S; Cuffe S; Finn S; Moore G; Gately K
Pharmacol Ther; 2020 Mar; 207():107454. PubMed ID: 31836451
[TBL] [Abstract][Full Text] [Related]
4. Mechanism-based combinations with Pim kinase inhibitors in cancer treatments.
Yang Q; Chen LS; Gandhi V
Curr Pharm Des; 2014; 20(42):6670-81. PubMed ID: 25341939
[TBL] [Abstract][Full Text] [Related]
5. PIM kinases: From survival factors to regulators of cell motility.
Santio NM; Koskinen PJ
Int J Biochem Cell Biol; 2017 Dec; 93():74-85. PubMed ID: 29108877
[TBL] [Abstract][Full Text] [Related]
6. Targeting PIM Kinases to Improve the Efficacy of Immunotherapy.
Clements AN; Warfel NA
Cells; 2022 Nov; 11(22):. PubMed ID: 36429128
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Insights that Targeting PIM for Cancer Therapy: Prospects and Obstacles.
Chen L; Mao W; Ren C; Li J; Zhang J
J Med Chem; 2024 Jan; 67(1):38-64. PubMed ID: 38164076
[TBL] [Abstract][Full Text] [Related]
8. Pim kinase isoforms: devils defending cancer cells from therapeutic and immune attacks.
Jinesh GG; Mokkapati S; Zhu K; Morales EE
Apoptosis; 2016 Nov; 21(11):1203-1213. PubMed ID: 27651368
[TBL] [Abstract][Full Text] [Related]
9. Pim kinases in hematological malignancies: where are we now and where are we going?
Mondello P; Cuzzocrea S; Mian M
J Hematol Oncol; 2014 Dec; 7():95. PubMed ID: 25491234
[TBL] [Abstract][Full Text] [Related]
10. Targeting the Pim kinases in multiple myeloma.
Keane NA; Reidy M; Natoni A; Raab MS; O'Dwyer M
Blood Cancer J; 2015 Jul; 5(7):e325. PubMed ID: 26186558
[TBL] [Abstract][Full Text] [Related]
11. PIM activity in tumours: A key node of therapy resistance.
Rebello RJ; Huglo AV; Furic L
Adv Biol Regul; 2018 Jan; 67():163-169. PubMed ID: 29111105
[TBL] [Abstract][Full Text] [Related]
12. PIM Kinases and Their Relevance to the PI3K/AKT/mTOR Pathway in the Regulation of Ovarian Cancer.
Aziz AUR; Farid S; Qin K; Wang H; Liu B
Biomolecules; 2018 Feb; 8(1):. PubMed ID: 29401696
[TBL] [Abstract][Full Text] [Related]
13. A serine/threonine protein PIM kinase as a biomarker of cancer and a target for anti-tumor therapy.
Panchal NK; Sabina EP
Life Sci; 2020 Aug; 255():117866. PubMed ID: 32479955
[TBL] [Abstract][Full Text] [Related]
14. The Pim kinases: new targets for drug development.
Swords R; Kelly K; Carew J; Nawrocki S; Mahalingam D; Sarantopoulos J; Bearss D; Giles F
Curr Drug Targets; 2011 Dec; 12(14):2059-66. PubMed ID: 21777193
[TBL] [Abstract][Full Text] [Related]
15. A review on structure-function mechanism and signaling pathway of serine/threonine protein PIM kinases as a therapeutic target.
Rout AK; Dehury B; Parida SN; Rout SS; Jena R; Kaushik N; Kaushik NK; Pradhan SK; Sahoo CR; Singh AK; Arya M; Behera BK
Int J Biol Macromol; 2024 May; 270(Pt 1):132030. PubMed ID: 38704069
[TBL] [Abstract][Full Text] [Related]
16. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
[TBL] [Abstract][Full Text] [Related]
17. PIM kinases inhibit AMPK activation and promote tumorigenicity by phosphorylating LKB1.
Mung KL; Eccleshall WB; Santio NM; Rivero-Müller A; Koskinen PJ
Cell Commun Signal; 2021 Jun; 19(1):68. PubMed ID: 34193159
[TBL] [Abstract][Full Text] [Related]
18. The oncogenic PIM kinase family regulates drug resistance through multiple mechanisms.
Isaac M; Siu A; Jongstra J
Drug Resist Updat; 2011; 14(4-5):203-11. PubMed ID: 21601509
[TBL] [Abstract][Full Text] [Related]
19. Activation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors.
An N; Xiong Y; LaRue AC; Kraft AS; Cen B
Cancer Res; 2015 Dec; 75(24):5318-28. PubMed ID: 26670562
[TBL] [Abstract][Full Text] [Related]
20. Targeting Pim kinases for cancer treatment: opportunities and challenges.
Le BT; Kumarasiri M; Adams JR; Yu M; Milne R; Sykes MJ; Wang S
Future Med Chem; 2015; 7(1):35-53. PubMed ID: 25582332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
